These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9183308)

  • 41. Does prior authorization of sibutramine improve medication compliance or weight loss?
    Risser JA; Vash PD; Nieto L
    Obes Res; 2005 Jan; 13(1):86-92. PubMed ID: 15761166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke.
    Derby LE; Myers MW; Jick H
    Br J Clin Pharmacol; 1999 May; 47(5):565-9. PubMed ID: 10336582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
    JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dexfenfluramine hydrochloride: an anorexigenic agent.
    Bever KA; Perry PJ
    Am J Health Syst Pharm; 1997 Sep; 54(18):2059-72. PubMed ID: 9377205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
    Enzi G
    Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial.
    Digenio AG; Mancuso JP; Gerber RA; Dvorak RV
    Ann Intern Med; 2009 Feb; 150(4):255-62. PubMed ID: 19221377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.
    Heymsfield SB; Greenberg AS; Fujioka K; Dixon RM; Kushner R; Hunt T; Lubina JA; Patane J; Self B; Hunt P; McCamish M
    JAMA; 1999 Oct; 282(16):1568-75. PubMed ID: 10546697
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dexfenfluramine influences dietary compliance and eating behavior, but dietary instruction may overrule its effect on food selection in obese subjects.
    Mathus-Vliegen LM; Res AM
    J Am Diet Assoc; 1993 Oct; 93(10):1163-5. PubMed ID: 8409140
    [No Abstract]   [Full Text] [Related]  

  • 49. Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women.
    Flechtner-Mors M; Ditschuneit HH; Yip I; Adler G
    Am J Clin Nutr; 1998 Apr; 67(4):611-5. PubMed ID: 9537607
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally].
    López-Alvarenga JC; Vargas JA; Schneider-Ehrenberg OP; Comuzzie AG; González J; Martínez JL
    Gac Med Mex; 2007; 143(2):109-14. PubMed ID: 17585697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prolonged weight loss with dexfenfluramine treatment in obese patients.
    Finer N; Craddock D; Lavielle R; Keen H
    Diabete Metab; 1987; 13(6):598-602. PubMed ID: 3329122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. d-fenfluramine treatment of binge eating disorder.
    Stunkard A; Berkowitz R; Tanrikut C; Reiss E; Young L
    Am J Psychiatry; 1996 Nov; 153(11):1455-9. PubMed ID: 8890680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A collaborative investigation of fenfluramine. Anorexigenic with sedative properties.
    Elliott BW
    Curr Ther Res Clin Exp; 1970 Aug; 12(8):502-15. PubMed ID: 4988837
    [No Abstract]   [Full Text] [Related]  

  • 54. New treatment for obesity: dexfenfluramine (Redux).
    Bihm B
    Medsurg Nurs; 1996 Oct; 5(5):360-2, 373. PubMed ID: 8981871
    [No Abstract]   [Full Text] [Related]  

  • 55. Body weight evolution during dexfenfluramine treatment after initial weight control.
    Finer N
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S25-9. PubMed ID: 1338319
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Activity of fenfluramine in obese subjects. Relation between dosage, plasma concentration of the drug and its effect on weight loss].
    Magnoni V; Boni S; Bonini LM; Zecca L; Bareggi SR
    Minerva Med; 1982 Jun; 73(24):1703-10. PubMed ID: 7088388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Drug therapy of obesity].
    Cairella M
    Clin Ter; 1978 Mar; 84(6):571-92. PubMed ID: 648107
    [No Abstract]   [Full Text] [Related]  

  • 58. A comparative trial of different regimens of fenfluramine and phentermine in obesity.
    Steel JM; Munro JF; Duncan LJ
    Practitioner; 1973 Aug; 211(262):232-6. PubMed ID: 4580610
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom.
    Finer N; Craddock D; Lavielle R; Keen H
    Clin Neuropharmacol; 1988; 11 Suppl 1():S179-86. PubMed ID: 3052816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pharmacologic management of obesity.
    Cerda JJ
    J Fla Med Assoc; 1997 Feb; 84(2):89-92. PubMed ID: 9066231
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.